Abstract A girl was diagnosed with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) due to pyrexia and hemoptysis for eight days. The girl was a school-age child with major clinical manifestations of pyrexia, skin rash, enlargement of bilateral cervical lymph nodes, conjunctival hyperaemia, red and cracked lips and strawberry-like tongue, followed by swelling of both hands and feet. Laboratory examination showed significant increases in white blood cell count, platelet count, C-reactive protein, erythrocyte sedimentation rate and liver enzymes, a significant reduction in albumin, and the presence of aseptic pyuria. After the first course of IVIG treatment, the girl still had recurrent pyrexia, with hemoptysis on day 2 after admission, and lung CT showed uneven luminance and patchy shadow. The symptoms were quickly alleviated after the second course of IVIG treatment combined with methylprednisolone and aspirin treatment. KD is a febrile disease characterized by multiple systemic vasculitis in childhood and can involve various organ systems such as the heart, lungs, kidneys and the nervous system. Therefore, it is necessary to carefully monitor and recognize the rare symptoms of KD, and early recognition of pulmonary complications of KD can avoid delay in diagnosis, prevent the development of more serious complications, and help with early treatment and disease recovery.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease:a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17):e927-e999.
[2]
Rowley AH. The complexities of the diagnosis and management of Kawasaki disease[J]. Infect Dis Clin North Am, 2015, 29(3):525-537.
[3]
Makino N, Nakamura Y, Yashiro M, et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012:from the results of the 22nd nationwide survey[J]. J Epidemiol, 2015, 25(3):239-245.
[4]
Umezawa T, Saji T, Matsuo N, et al. Chest x-ray findings in the acute phase of Kawasaki disease[J]. Pediatr Radiol, 1989, 20(1-2):48-51.
[5]
Singh S, Gupta A, Jindal AK, et al. Pulmonary presentation of Kawasaki disease - a diagnostic challenge[J]. Pediatr Pulmonol, 2018, 53(1):103-107.
[6]
Batra K, Chamarthy M, Chate RC, et al. Pulmonary vasculitis:diagnosis and endovascular therapy[J]. Cardiovasc Diagn Ther, 2018, 8(3):297-315.
[7]
Vaidya PC, Narayanan K, Suri D, et al. Pulmonary presentation of Kawasaki disease:an unusual occurrence[J]. Int J Rheum Dis, 2017, 20(12):2227-2229.
[8]
Soriano-Ramos M, Martínez-Del Val E, Negreira Cepeda S, et al. Risk of coronary artery involvement in Kawasaki disease[J]. Arch Argent Pediatr, 2016, 114(2):107-113.
[9]
Portman MA, Olson A, Soriano B, et al. Etanercept as adjunctive treatment for acute Kawasaki disease:study design and rationale[J]. Am Heart J, 2011, 161(3):494-499.
[10]
Saneeymehri S, Baker K, So TY. Overview of pharmacological treatment options for pediatric patients with refractory Kawasaki disease[J]. J Pediatr Pharmacol Ther, 2015, 20(3):163-177.
[11]
Kobayashi T, Kobayashi T, Morikawa A, et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease[J]. J Pediatr, 2013, 163(2):521-526.
[12]
Dimitriades VR, Brown AG, Gedalia A. Kawasaki disease:pathophysiology, clinical manifestations, and management[J]. Curr Rheumatol Rep, 2014, 16(6):423.
[13]
Galeotti C, Bayry J, Kone-Paut I, et al. Kawasaki disease:aetiopathogenesis and therapeutic utility of intravenous immunoglobulin[J]. Autoimmun Rev, 2010, 9(6):441-448.
